Influence of Macrolide Maintenance Therapy and Bacterial Colonisation on Exacerbation Frequency and Progression of COPD, a Randomized Double-blind Placebo-controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 92
- 试验地点
- 1
- 主要终点
- Reduction in number of exacerbations
研究概览
简要总结
To assess whether maintenance treatment with macrolide antibiotics in COPD patients with three or more exacerbations in the preceding year of inclusion can decrease the exacerbation rate in the year of treatment.
详细描述
COPD is characterized by progressive development of airflow limitation that is poorly reversible. Because of a poor understanding of COPD pathogenesis, treatment is mostly symptomatic and new therapeutic strategies are limited. There is a direct relationship between the severity of the disease and the intensity of the inflammatory response.One of the hypothesis for persistent airway inflammation is that the presence of recurrent infections is responsible for this condition.
Macrolide antibiotics have a bacteriostatic as well as anti-inflammatory properties. This clinical trial will investigate whether maintenance treatment with macrolide antibiotics during 1 year in people with 3 or more exacerbations in the preceding year of inclusion can decrease the exacerbation rate in that same year of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of COPD according to GOLD criteria (FEV1/FVC<70%), classification into GOLD I (FEV1 70-100% predicted), GOLD II (FEV1 50-70% predicted), GOLD III (FEV1 30- 50% predicted) or GOLD IV (FEV1 ≤ 30% predicted)
- •Age ≥ 18 years
- •Three or more exacerbations of COPD in one year for which a course of prednisone and/or antibiotic therapy was started
- •Clinically stable during 1 month. Patients have to be free of COPD exacerbation or respiratory tract infection within a month prior to involvement in the study and they should not have received a high dose of systemic glucocorticoids or antibiotics in this period
- •Informed consent
排除标准
- •Use of antibiotics or high dose of systemic steroids within a month prior to involvement in the study.
- •Addition of inhalation steroids to the patient's therapy regimen, shortly before entering the study.
- •Pregnant or lactating women.
- •Allergy to macrolides.
- •Liver disease (alanine transaminase and/or aspartate transaminase levels 2 or more times the upper limit of normal).
- •Asthma, defined as episodic symptoms of airflow obstruction which is reversible with bronchodilators, assessed with lung function testing.
- •Presence of a malignancy which is clinically active.
- •Bronchiectasis.
- •Malignancy of any kind for which the subject is under treatment or is being monitored as part of follow up after treatment.
- •Heart failure.
- •Use of drugs which can adversely interact with macrolides and for which therapeutic monitoring cannot be undertaken.
研究组 & 干预措施
Azithromycin
Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin
干预措施: Azithromycin (Drug)
Placebo
Subjects in this group will receive 3 times a week placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Reduction in number of exacerbations
时间窗: 1 year
次要结局
- Time till next exacerbation.(Whenever an exacerbation of COPD occurs.)
- Assess type D personality by DS-14 questionnaire.(Day 1 and month 12.)
- Disease specific health related quality of life measured by St. George's Respiratory Questionnaire (SGRQ)(Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation.)
- Lung function parameters (FEV1 (L), FVC (L), FRC (L), RV (L), TLC(L), IC (L), 6 minute walking distance)(Day 1. Also 3, 6, 9 and 12 months.)
- Indication of anxiety and depression by Hospital Anxiety Depression Scale (HADS)(Day 1. Also 3, 6, 9 and 12 months.)
- Microbiology of sputum (culture and PCR).(Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation of COPD.)
- Measurement of inflammatory markers in sputum and serum.(Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation of COPD.)
- Adverse events of treatment.(Day 1. Also 3, 6, 9 and 12 months. Whenever adverse events occur.)
- Length of hospital stay.(Whenever admission to hospital is required for an exacerbation of COPD.)
- Generic health status measured by 12-Item Short Form Health Survey (SF-12).(Day 1, month 3, 6, 9 and 12. In case of an exacerbation.)
- Decrease in percentage of clinical versus outdoor department exacerbations.(Month 12.)
- Effect of maintenance macrolides on intestinal bacterial restistancy patterns(Day 1, month 6 and month 12)
- Serology and PCR for atypical microorganisms in serum(day 1. In case of an exacerbation.)
- Intestinal bacterial resistance patterns(Day 1, month 6 and month 12)
研究者
R.S. Djamin
MD
Amphia Hospital